Drugmakers Spar Over Clinical Trial Rules For Biosimilars
Generics makers urged the U.S. Food and Drug Administration on Monday not to require clinical trials for proposed biosimilars, claiming there is "no scientific basis" for FDA concerns about immune reactions,...To view the full article, register now.
Already a subscriber? Click here to view full article